newsfilter
← Latest News
GlobeNewswire·

Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy

JBIO
  • Jade Biosciences will host a conference call & webcast on Monday, June 1, 2026, at 8:00 a.m. ET to discuss Phase 1 healthy volunteer study results for JADE101.
  • The study data aims to define the dosing strategy & characterize JADE101 as a potentially differentiated, disease-modifying anti-APRIL monoclonal antibody for immunoglobulin A nephropathy (IgAN).
  • Investors & the public may register via the "Events and Presentations" page on JadeBiosciences.com for the live webcast or register separately for dial-in details & a unique PIN.
  • A replay of the webcast will be available on the company's website shortly after the call concludes.
  • IgAN is a chronic autoimmune kidney disease affecting approximately 169,000 people in the U.S., often diagnosed in young adults, characterized by IgA immune complex deposits that can lead to kidney failure.
  • JADE101 is a fully human monoclonal antibody that selectively blocks APRIL with ultra-high binding affinity & is engineered for half-life extension.
  • Preclinical studies in non-human primates showed potent, sustained IgA suppression after a single dose, with a serum half-life of approximately 27 days.
  • JADE101 was designed to avoid high molecular weight immune complexes to support predictable pharmacokinetics, reduced immunogenicity, & potential for infrequent subcutaneous dosing.
  • Jade's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, & JADE301, an undisclosed antibody program.
  • Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.
  • The release includes forward-looking statements regarding expectations for JADE101's clinical profile, efficacy, safety, & regulatory approvals, noting risks such as trial delays, adverse events, or lack of commercial viability.
  • Media & investor inquiries can be directed to Priyanka Shah at Media@JadeBiosciences.com or IR@JadeBiosciences.com, or by calling 908-447-6134.